$EQ

Zedelmayer Christine sold $90K of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 30,208 shares of Equillium, Inc. (EQ) at $2.98 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published May 29, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosure may slightly pressure sentiment, but the presence of a pre-arranged 10b5-1 plan generally limits fundamental interpretation.

02

Market read

Traders may monitor for patterns in insider activity, but this specific filing is unlikely to drive a major repricing absent other catalysts.

03

What to watch

10b5-1 plans are often scheduled well in advance; without additional context (e.g., multiple consecutive sales, option exercises), directional inference is weak.

Relevance 6/10Novelty 2/10Timing: Filed today; sale executed 2026-05-28

Background

This is an SEC Form 4 insider transaction: an officer (COO) reports an open-market sale of company shares.

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium COO Christine Zedelmayer sold 30,208 shares in an open-market transaction disclosed on Form 4.

Expected impact

Likely limited/short-lived impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing specifies an open-market sale under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale still provides a datapoint—if EQ is volatile, traders may overreact and create a short-term dislocation opportunity.

Key entities

  • Equillium, Inc.

    Subject of the insider Form 4 disclosure; COO sold shares under a 10b5-1 plan.

  • Christine Zedelmayer

    COO and reporting officer who sold 30,208 shares at $2.98/share.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP